Phase Ⅱ Study of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

NCT06685887 Phase 2 RECRUITING

This study is a single-center, prospective, phase II clinical trial aimed at assessing the impact of HIPEC combined with systemic chemotherapy and immune checkpoint inhibitors on the R0 resection rate in patients with peritoneal metastasis from gastric cancer. Furthermore, it seeks to analyze the effects of this treatment strategy on overall survival (OS), progression-free survival (PFS), PCI and adverse reaction rates.

Details

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	RECRUITING
Enrolment	34
Start date	2025-02-15
Completion	2027-12

Conditions

• Gastric Cancer

Interventions

• HIPEC
• SOX
• Immune Checkpoint Inhibitors

Primary outcomes

• R0 resection rate — 1 year
  The proportion of patients who achieved R0 resection

Countries

China